CompanyGraph
Nanosonics Limited
NAN · ASX · Australia
Price data from its NAN listing on CXA
nanosonics.com.auFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 1
- FinancialsAltman Z-Score 11.11: safe zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.09BAUD779.06M · vs all stocks (USD)
Trailing P/E
52.00xvs Medical Instruments & Supplies peers
Revenue (TTM)
207.26MAUD148.82M · vs all stocks (USD)
Profit Margin
9.92%vs Medical Instruments & Supplies peers
Beta
1.20xvs all stocks
52-Week Change
-11.68%vs all stocks
Market Capitalization
1.09BAUD779.06M · vs all stocks (USD)
Enterprise Value
951.03MAUD682.84M · vs all stocks (USD)
Trailing P/E
52.00xvs Medical Instruments & Supplies peers
Forward P/E
49.57xvs Medical Instruments & Supplies peers
Price to Sales (TTM)
5.25xvs Medical Instruments & Supplies peers
Price to Book (MRQ)
5.03xvs Medical Instruments & Supplies peers
Enterprise to Revenue
4.59xvs Medical Instruments & Supplies peers
Enterprise to EBITDA
38.57xvs Medical Instruments & Supplies peers
Profit Margin
9.92%vs Medical Instruments & Supplies peers
Operating Margin
8.92%vs Medical Instruments & Supplies peers
Return on Assets (TTM)
4.61%vs Medical Instruments & Supplies peers
Return on Equity (TTM)
10.06%vs Medical Instruments & Supplies peers
Revenue (TTM)
207.26MAUD148.82M · vs all stocks (USD)
Revenue per Share (TTM)
0.6830AUDUpdated Aug 22, 2026Quarterly Revenue Growth
9.20%vs Medical Instruments & Supplies peers
Gross Profit (TTM)
159.92MAUD114.82M · vs all stocks (USD)
EBITDA (TTM)
31.82MAUD22.85M · vs all stocks (USD)
Net Income (TTM)
20.56MAUD14.76M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-1.20%vs Medical Instruments & Supplies peers
Operating Cash Flow (TTM)
29.40MAUD21.11M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
9.13MAUD6.56M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00AUDUpdated Aug 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Instruments & Supplies peers
Revenue
198.93MAUDFY2025 · Jun 30, 2025Cost of Goods Sold
43.27MAUDFY2025 · Jun 30, 2025Gross Profit
155.66MAUDFY2025 · Jun 30, 2025Operating Income
8.93MAUD6.41M · vs all stocks (USD)
Pre-tax Income
22.29MAUDFY2025 · Jun 30, 2025Income Tax Expense
1.61MAUDFY2025 · Jun 30, 2025Net Income
20.68MAUDFY2025 · Jun 30, 2025EBIT
23.75MAUDFY2025 · Jun 30, 2025EBITDA (Income Statement)
31.82MAUDFY2025 · Jun 30, 2025Research & Development
34.70MAUDFY2025 · Jun 30, 2025Selling, General & Administrative
103.97MAUDFY2025 · Jun 30, 2025Non-operating Interest Income
5.94MAUDFY2025 · Jun 30, 2025Non-operating Interest Expense
1.46MAUDFY2025 · Jun 30, 2025EPS (Basic)
0.0682AUDFY2025 · Jun 30, 2025EPS (Diluted)
0.0669AUDFY2025 · Jun 30, 2025Basic Shares Outstanding
303.40MSharesFY2025 · Jun 30, 2025Diluted Shares Outstanding
303.40MSharesFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
161.64MAUDFY2025 · Jun 30, 2025Income Tax Paid
2.59MAUDFY2025 · Jun 30, 2025Capital Expenditures
-8.71MAUDFY2025 · Jun 30, 2025Net Investing Cash Flow
-8.71MAUDFY2025 · Jun 30, 2025Other Financing Charges
-3.25MAUDFY2025 · Jun 30, 2025Net Financing Cash Flow
-2.94MAUDFY2025 · Jun 30, 2025Shares Outstanding
303.63MSharesUpdated Aug 22, 2026Float Shares
254.96MSharesUpdated Aug 22, 2026% Held by Insiders
15.88%vs all stocks
% Held by Institutions
64.82%vs all stocks
Total Cash (MRQ)
159.83MAUD114.76M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5270AUDUpdated Aug 22, 2026Total Debt (MRQ)
6.67MAUD4.79M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0304xvs Medical Instruments & Supplies peers
Current Ratio (MRQ)
6.40xvs Medical Instruments & Supplies peers
Book Value per Share (MRQ)
0.7240AUDUpdated Aug 22, 2026Total Assets
272.48MAUD195.64M · vs all stocks (USD)
Total Current Assets
225.32MAUDFY2025 · Jun 30, 2025Total Liabilities
62.57MAUDFY2025 · Jun 30, 2025Total Non-current Assets
47.16MAUDFY2025 · Jun 30, 2025Total Non-current Liabilities
22.78MAUDFY2025 · Jun 30, 2025Total Current Liabilities
39.79MAUDFY2025 · Jun 30, 2025Cash
20.44MAUDFY2025 · Jun 30, 2025Cash Equivalents
140.85MAUDFY2025 · Jun 30, 2025Cash & Cash Equivalents
161.29MAUDFY2025 · Jun 30, 2025Accounts Receivable
32.31MAUDFY2025 · Jun 30, 2025Inventory
18.63MAUDFY2025 · Jun 30, 2025Accounts Payable
1.53MAUDFY2025 · Jun 30, 2025Short-term Debt
3.42MAUDFY2025 · Jun 30, 2025Deferred Revenue
14.66MAUDFY2025 · Jun 30, 2025Long-term Debt
4.26MAUDFY2025 · Jun 30, 2025Common Stock (Book)
114.86MAUDFY2025 · Jun 30, 2025Retained Earnings
58.39MAUDFY2025 · Jun 30, 2025Total Shareholders' Equity
209.91MAUD150.72M · vs all stocks (USD)
52-Week Low
2.94AUDUpdated Aug 22, 202652-Week High
4.77AUDUpdated Aug 22, 202652-Week Change
-11.68%vs all stocks
Beta
1.20xvs all stocks
50-Day MA
3.29AUDUpdated Aug 22, 2026200-Day MA
3.62AUDUpdated Aug 22, 2026Avg 10-Day Volume
465.26KSharesUpdated Aug 22, 2026Avg 30-Day Volume
388.38KSharesUpdated Aug 22, 2026Diluted EPS (TTM)
0.0700AUDUpdated Aug 22, 2026Other Income / Expense
813.00KAUDFY2025 · Jun 30, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 11.11: safe zoneNotable
Altman Z-Score: 11.11
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Huachangda Intelligent Equipment Group Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Shandong University Electric Power Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Shenzhen Sunnypol Optoelectronic Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Shenyang Blue Silver Industry Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Sichuan Chuanhuan Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Jiangsu Boiln Plastics Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Jiangsu Canlon Building Materials Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Middle East Healthcare Company
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Shikoku Kasei Holdings Corporation
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Shandong Ruifeng Chemical Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Harmony Biosciences Holdings, Inc.
4 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Catalyst Pharmaceuticals Inc.
4 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Selamat Sempurna Tbk
4 interpretationsMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity